Author: Chen, Sai-Juan ; Sun, Xiao-Jian ; Huang, Qiu-Hua ; Li, Ning-Zhe ; Xie, Yin-Yin ; Zhang, Jianming ; Hu, Xi-Bo ; Chen, Zhu ; Wang, Fudi ; Feng, Chang-Zhou

01 Jan 2022·International Journal of Biological SciencesQ2 · BIOLOGY

Cancer-associated adipocytes promote the invasion and metastasis in breast cancer through LIF/CXCLs positive feedback loop

Q2 · BIOLOGY

ArticleOA

Author: He, Xi ; Wang, Lieliang ; Li, Honghui ; Zhou, Chong ; Wu, Yudong ; Cheng, Zhongman ; Luo, Daya ; Yan, Xiaohua ; Tang, Yunpeng ; Xiong, Xiangyang ; Xie, Caifeng ; Tong, Chang

Cancer-associated adipocytes (CAAs), which are adipocytes transformed by cancer cells, are of great importance in promoting the progression of breast cancer. However, the underlying mechanisms involved in the crosstalk between cancer cells and adipocytes are still unknown. Here we report that CAAs and breast cancer cells communicate with each other by secreting the cytokines leukemia inhibitory factor (LIF) and C-X-C subfamily chemokines (CXCLs), respectively. LIF is a pro-inflammatory cytokine secreted by CAAs, which promotes migration and invasion of breast cancer cells via the Stat3 signaling pathway. The activation of Stat3 induced the secretion of glutamic acid-leucine-arginine (ELR) motif CXCLs (CXCL1, CXCL2, CXCL3 and CXCL8) in tumor cells. Interestingly, CXCLs in turn activated the ERK1/2/NF-κB/Stat3 signaling cascade to promote the expression of LIF in CAAs. In clinical breast cancer pathology samples, the up-regulation of LIF in paracancerous adipose tissue was positively correlated with the activation of Stat3 in breast cancer. Furthermore, we verified that adipocytes enhanced lung metastasis of breast cancer cells, and the combination of EC330 (targeting LIF) and SB225002 (targeting C-X-C motility chemokine receptor 2 (CXCR2)) significantly reduced lung metastasis of breast cancer cells in vivo. Our findings reveal that the interaction of adipocytes with breast cancer cells depends on a positive feedback loop between the cytokines LIF and CXCLs, which promotes breast cancer invasion and metastasis.

03 Jul 2020·Journal of Molecular Cell BiologyQ2 · BIOLOGY

EC330, a small-molecule compound, is a potential novel inhibitor of LIF signaling

Q2 · BIOLOGY

LetterOA

Author: Nickisch, Klaus ; Santhamma, Bindu ; Wu, Fangnan ; Feng, Zhaohui ; Ahmed, Gulzar ; Wang, Jianming ; Vadlamudi, Ratna K ; Yue, Xuetian ; Kim, Kaitlin ; Zhang, Kam Y J ; Hu, Wenwei ; Viswanadhapalli, Suryavathi ; Dileep, Kalarickal V

100 Deals associated with EC-330

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neoplasms	Preclinical	US	University of Texas Health Science Center At San Antonio	-
Neoplasms	Discovery	US	Evestra, Inc.	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

EC-330

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation